抄録
Monoamine oxidase type B (MAO-B) inhibitors have neuroprotective properties in addition to their primary pharmacologic function. We examined the effects of selegiline, an irreversible MAO-B inhibitor, on the expression levels of survivin mRNA and lipid peroxidation in the corpus striata of 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induccd Parkinsonian roice. Mice were treated with normal saline (vehicle as control), MPTP alone (30 mg/kg of body weight), MPTP with low-dose of selegiline (0-1 mg/kg of body weight), or MPTP with high-dose of selegiline (1.0 mg/kg of body weight). A consecutive 7-day oral treatment of MPTP alone d'd not influence survivin mRNA expression. Selegiline treatment together with MPTP significantly uprcgulated survivin expression at both low- and high-doses. Interestingly, lipid Peroxidation was significantly suppressed by a low-dose of selegiline but not by a high-dose. These results suggest that selegiline has Pleiotropic effects; the upregulation effects on survivin mRNA expression are likely to be '"dependent from its primary pharmacological Properties (MAO-B inhibition), whereas the inhibitory effects on lipid peroxidation seem to be associated with its primary pharmacological properties. In addition to conventional dopamine supplementation therapy, selegiline might serve as a novel pharmacological therapeutic strategy for Parkinson's disease through its antiapoptotic properties via survivin induction as well as its antioxidative properties.
| 元の言語 | English |
|---|---|
| ページ（範囲） | 29-37 |
| ページ数 | 9 |
| ジャーナル | Current Topics in Pharmacology |
| 巻 | 18 |
| 発行部数 | 1-2 |
| 出版物ステータス | Published - 2014 |
| 外部発表 | Yes |
Fingerprint
ASJC Scopus subject areas
- Pharmacology (medical)
- Pharmacology
これを引用
A possible novel pharmacological therapy for Parkinson's disease using the pleiotropic property of Selegiline. / Ono, Shin Ichi; Sorte, Ryuji; Tokuda, Ei Ichi.
：: Current Topics in Pharmacology, 巻 18, 番号 1-2, 2014, p. 29-37.研究成果: Article
}
TY - JOUR
T1 - A possible novel pharmacological therapy for Parkinson's disease using the pleiotropic property of Selegiline
AU - Ono, Shin Ichi
AU - Sorte, Ryuji
AU - Tokuda, Ei Ichi
PY - 2014
Y1 - 2014
N2 - Monoamine oxidase type B (MAO-B) inhibitors have neuroprotective properties in addition to their primary pharmacologic function. We examined the effects of selegiline, an irreversible MAO-B inhibitor, on the expression levels of survivin mRNA and lipid peroxidation in the corpus striata of 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induccd Parkinsonian roice. Mice were treated with normal saline (vehicle as control), MPTP alone (30 mg/kg of body weight), MPTP with low-dose of selegiline (0-1 mg/kg of body weight), or MPTP with high-dose of selegiline (1.0 mg/kg of body weight). A consecutive 7-day oral treatment of MPTP alone d'd not influence survivin mRNA expression. Selegiline treatment together with MPTP significantly uprcgulated survivin expression at both low- and high-doses. Interestingly, lipid Peroxidation was significantly suppressed by a low-dose of selegiline but not by a high-dose. These results suggest that selegiline has Pleiotropic effects; the upregulation effects on survivin mRNA expression are likely to be '"dependent from its primary pharmacological Properties (MAO-B inhibition), whereas the inhibitory effects on lipid peroxidation seem to be associated with its primary pharmacological properties. In addition to conventional dopamine supplementation therapy, selegiline might serve as a novel pharmacological therapeutic strategy for Parkinson's disease through its antiapoptotic properties via survivin induction as well as its antioxidative properties.
AB - Monoamine oxidase type B (MAO-B) inhibitors have neuroprotective properties in addition to their primary pharmacologic function. We examined the effects of selegiline, an irreversible MAO-B inhibitor, on the expression levels of survivin mRNA and lipid peroxidation in the corpus striata of 1-methyl-4-phenyl 1,2,3,6 tetrahydropyridine (MPTP)-induccd Parkinsonian roice. Mice were treated with normal saline (vehicle as control), MPTP alone (30 mg/kg of body weight), MPTP with low-dose of selegiline (0-1 mg/kg of body weight), or MPTP with high-dose of selegiline (1.0 mg/kg of body weight). A consecutive 7-day oral treatment of MPTP alone d'd not influence survivin mRNA expression. Selegiline treatment together with MPTP significantly uprcgulated survivin expression at both low- and high-doses. Interestingly, lipid Peroxidation was significantly suppressed by a low-dose of selegiline but not by a high-dose. These results suggest that selegiline has Pleiotropic effects; the upregulation effects on survivin mRNA expression are likely to be '"dependent from its primary pharmacological Properties (MAO-B inhibition), whereas the inhibitory effects on lipid peroxidation seem to be associated with its primary pharmacological properties. In addition to conventional dopamine supplementation therapy, selegiline might serve as a novel pharmacological therapeutic strategy for Parkinson's disease through its antiapoptotic properties via survivin induction as well as its antioxidative properties.
KW - Lipid peroxidation
KW - Neuroprotection
KW - Parkinson's disease
KW - Selegiline
KW - Survivin
UR - http://www.scopus.com/inward/record.url?scp=84949210282&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84949210282&partnerID=8YFLogxK
M3 - Article
AN - SCOPUS:84949210282
VL - 18
SP - 29
EP - 37
JO - Current Topics in Pharmacology
JF - Current Topics in Pharmacology
SN - 0972-4559
IS - 1-2
ER -